Honz Pharmaceutical Co., Ltd.
300086.SZ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.5B
Close$
$-1.78
133.6% downside
Current Fair Value
133.6% downsideOvervalued by 133.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.50 Billion |
|---|---|
| Enterprise Value | $2.91 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.51 |
| Beta | 0.27 |
| Outstanding Shares | 455,124,411 |
Return
| Return on Equity | -24.09% |
|---|---|
| Return on Assets | -12.20% |
| Return on Invested Capital | -18.19% |
Valuation & Multiples
| P/E Ratio | -12.05 |
|---|---|
| PEG | 22.89 |
| Price to Sales | - |
| Price to Book Ratio | 5.3 |
| Enterprise Value to Revenue | 7.68 |
| Enterprise Value to EBIT | -13.97 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.49 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Honz Pharmaceutical Co., Ltd.
540 employees
CEO: Liping Hong Honz Pharmaceutical Co., Ltd. is a Chinese enterprise based in Guangzhou, primarily engaged in the creation, production, and commercialization of pharmaceutical drugs. While specializing in pediatric medications, the company also provide...